Xencor, Inc. (NASDAQ:XNCR – Get Free Report) saw unusually-high trading volume on Monday . Approximately 438,042 shares traded hands during trading, a decline of 45% from the previous session’s volume of 803,017 shares.The stock last traded at $18.8690 and had previously closed at $17.47.
Wall Street Analysts Forecast Growth
XNCR has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Truist Financial decreased their target price on shares of Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. JPMorgan Chase & Co. boosted their price target on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Monday, May 11th. Finally, Zacks Research raised Xencor from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.25.
Get Our Latest Analysis on XNCR
Xencor Trading Up 11.9%
Xencor (NASDAQ:XNCR – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). The firm had revenue of $4.52 million for the quarter, compared to analysts’ expectations of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. Xencor’s revenue was down 86.2% on a year-over-year basis. During the same period last year, the firm posted ($0.66) EPS. Equities research analysts expect that Xencor, Inc. will post -3.88 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC boosted its position in shares of Xencor by 6.5% in the 4th quarter. ProShare Advisors LLC now owns 16,853 shares of the biopharmaceutical company’s stock valued at $258,000 after purchasing an additional 1,026 shares during the period. Cerity Partners LLC raised its holdings in Xencor by 3.8% during the 4th quarter. Cerity Partners LLC now owns 31,302 shares of the biopharmaceutical company’s stock worth $479,000 after buying an additional 1,143 shares during the period. State of Tennessee Department of Treasury raised its holdings in Xencor by 6.2% during the 2nd quarter. State of Tennessee Department of Treasury now owns 30,721 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 1,784 shares during the period. Diversified Trust Co. lifted its stake in Xencor by 13.8% during the fourth quarter. Diversified Trust Co. now owns 18,442 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 2,242 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its stake in Xencor by 3.3% during the second quarter. CANADA LIFE ASSURANCE Co now owns 70,015 shares of the biopharmaceutical company’s stock valued at $550,000 after buying an additional 2,256 shares in the last quarter.
About Xencor
Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.
The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.
Read More
- Five stocks we like better than Xencor
- Amazon’s AI Spending Is About to Face Its Most Important AWS Test Yet
- AI Data Centers Need Power, and These 2 Industrials Are Cashing In
- 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama
- Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.
